(AOF) – Poxel “remains focused on seeking additional funding in order to execute its strategic plan in rare diseases”. The biotech specialist in innovative treatments against serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH), declares that its financing horizon runs until March 2024 “including only the tranches already drawn or fully available from the line of equity financing set up with Iris”.
At the beginning of November, Poxel estimated that its financing horizon ran until the end of the second quarter of 2025.
It is now planning a new savings plan, including a “significant” reduction in the workforce, in order to adapt resources to the current needs of the company “while awaiting the relaunch of its research and development activities”.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
